Diagnostic accuracy of the aspartate aminotransferase-to-platelet ratio index for the prediction of hepatitis C-related fibrosis: A systematic review

Hepatology

Volumn 46, Issue 3, 2007, Pages 912-921

  Shaheen, Abdel Aziz M ^a   Myers, Robert P ^a,b  

^a UNIVERSITY OF CALGARY   (Canada)

^b UNIVERSITY OF CALGARY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ASPARTATE AMINOTRANSFERASE;

ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CLINICAL TRIAL; DIAGNOSTIC ACCURACY; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIVER BIOPSY; LIVER CIRRHOSIS; LIVER FIBROSIS; META ANALYSIS; PREDICTION; PREVALENCE; PRIORITY JOURNAL; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; SUPERINFECTION; SYSTEMATIC REVIEW; THROMBOCYTE;

ASPARTATE AMINOTRANSFERASES; BIOLOGICAL MARKERS; HEPATITIS C, CHRONIC; HIV INFECTIONS; HUMANS; LIVER CIRRHOSIS; PLATELET COUNT; PROGNOSIS;

EID: 34548786091     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1002/hep.21835     Document Type: Article

References (77)

1. Hepatitis C-global prevalence (update). Wkly Epidemiol Rec 2000;75:18-19.
2. Pawlotsky JM. Current and future concepts in hepatitis C therapy. Semin Liver Dis 2005;25:72-83.
3. Thomas DL, Seeff LB. Natural history of hepatitis C. Clin Liver Dis 2005;9:383-398, vi.
4. Friedman LS. Controversies in liver biopsy: who, where, when, how, why? Curr Gastroenterol Rep 2004;6:30-36.
5. Bedossa P, Dargere D, Paradis V. Sampling variability of liver fibrosis in chronic hepatitis C. HEPATOLOGY 2003;38:1449-1457.
6. McHutchison J, Poynard T, Afdhal N. Fibrosis as an end point for clinical trials in liver disease: a report of the international fibrosis group. Clin Gastroenterol Hepatol 2006;4:1214-1220.
7. Sandrin L, Fourquet B, Hasquenoph JM, Yon S, Founder C, Mai F, et al. Transient elastography: a new noninvasive method for assessment of hepatic fibrosis. Ultrasound Med Biol 2003;29:1705-1713.
8. Sebastiani G, Alberti A. Non invasive fibrosis biomarkers reduce but not substitute the need for liver biopsy. World J Gastroenterol 2006;12:3682-3694.
9. Rockey DC, Bissell DM. Noninvasive measures of liver fibrosis. HEMATOLOGY 2006;43(2 Suppl 1):S113-S120.
10. Patel K, Gordon SC, Jacobson I, Hezode C, Oh E, Smith KM, et al. Evaluation of a panel of non-invasive serum markers to differentiate mild from moderate-to-advanced liver fibrosis in chronic hepatitis C patients. J Hepatol 2004;41:935-942.
11. Cales P, Oberti F, Michalak S, Hubert-Fouchard I, Rousselet MC, Konate A, et al. A novel panel of blood markers to assess the degree of liver fibrosis. HEPATOLOGY 2005;42:1373-1381.
12. Adams LA, Bulsara M, Rossi E, DeBoer B, Speers D, George J, et al. Hepascore: an accurate validated predictor of liver fibrosis in chronic hepatitis C infection. Clin Chem 2005;51:1867-1873.
13. Rosenberg WM, Voelker M, Thiel R, Becka M, Burt A, Schuppan D, et al. Serum markers detect the presence of liver fibrosis: a cohort study. Gastroenterology 2004;127:1704-1713.
14. Forns X, Ampurdanes S, Llovet JM, Aponte J, Quinto L, Martinez-Bauer E, et al. Identification of chronic hepatitis C patients without hepatic fibrosis by a simple predictive model. HEPATOLOGY 2002;36:986-992.
15. Sud A, Hui JM, Farrell GC, Bandara P, Kench JG, Fung C, et al. Improved prediction of fibrosis in chronic hepatitis C using measures of insulin resistance in a probability index. HEPATOLOGY 2004;39:1239-1247.
16. Imbert-Bismut F, Ratziu V, Pieroni L, Charlotte F, Benhamou Y, Poynard T. Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: a prospective study. Lancet 2001;357:1069-1075.
17. Wai CT, Greenson JK, Fontana RJ, Kalbfleisch JD, Marrero JA, Conjeevaram HS, et al. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. HEPATOLOGY 2003;38:518-526.
18. Deville WL, Buntinx F, Bouter LM, Montori VM, de Vet HC, van der Windt DA, et al. Conducting systematic reviews of diagnostic studies: didactic guidelines. BMC Med Res Methodol 2002;2:9.
19. Dickersin K, Scherer R, Lefebvre C. Identifying relevant studies for systematic reviews. BMJ 1994;309:1286-1291.
20. Whiting P, Rutjes AW, Dinnes J, Reitsma J, Bossuyt PM, Kleijnen J. Development and validation of methods for assessing the quality of diagnostic accuracy studies. Health Technol Assess 2004;8:iii, 1-234.
21. Whiting PF, Westwood ME, Rutjes AW, Reitsma JB, Bossuyt PM, Kleijnen J. Evaluation of QUADAS, a tool for the quality assessment of diagnostic accuracy studies. BMC Med Res Methodol 2006;6:9.
22. Intraobserver and interobserver variarions in liver biopsy interpretation in patients with chronic hepatitis C: the French METAVIR Cooperative Study Group. HEPATOLOGY 1994;20:15-20.
23. Batts KP, Ludwig J. Chronic hepatitis: an update on terminology and reporting. Am J Surg Pathol 1995;19:1409-1417.
24. Scheuer PJ. Classification of chronic viral hepatitis: a need for reassessment. J Hepatol 1991;13:372-374.
25. Ishak K, Baptista A, Bianchi L, Callea F, De Groote J, Gudat F, et al. Histological grading and staging of chronic hepatitis. J Hepatol 1995;22:696-699.
26. Strader DB, Wright T, Thomas DL, Seeff LB. Diagnosis, management, and treatment of hepatitis C. HEPATOLOGY 2004;39:1147-1171.
27. Moses LE, Shapiro D, Littenberg B. Combining independent studies of a diagnostic test into a summary ROC curve: data-analytic approaches and some additional considerations. Stat Med 1993;12:1293-1316.
28. Walter SD. Properties of the summary receiver operating characteristic (SROC) curve for diagnostic test data. Stat Med 2002;21:1237-1256.
29. Dukic V, Gatsonis C. Meta-analysis of diagnostic test accuracy assessment studies with varying number of thtesholds. Biometrics 2003;59:936-946.
30. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986;7:177-188.
31. Glas AS, Lijmer JG, Prins MH, Bonsel GJ, Bossuyt PM. The diagnostic odds ratio: a single indicator of test performance. J Clin Epidemiol 2003;56:1129-1135.
32. Deeks JJ. Sysrematic reviews in health care: systematic reviews of evaluations of diagnostic and screening tests. Br Med J 2001;323:157-162.
33. Doust JA, Glasziou PP, Pietrzak E, Dobson AJ. A systematic review of the diagnostic accuracy of natriuretic peptides for heart failure. Arch Intern Med 2004;164:1978-1984.
34. Reitsma JB, Glas AS, Rutjes AW, Scholten RJ, Bossuyt PM, Zwinderman AH. Bivariate analysis of sensitivity and specificity produces informative summary measures in diagnostic reviews. J Clin Epidemiol 2005;58:982-990.
35. Schmid CH, Stark PC, Berlin JA, Landais P, Lau J. Meta-regression detected associations between heterogeneous treatment effects and studylevel, but not patient-level, factors. J Clin Epidemiol 2004;57:683-697.
36. Cochran WG. The combination of estimates from different experiments. Biometrics 1954;10:101-129.
37. Deeks JJ, Macaskill P, Irwig L. The performance of tests of publication bias and other sample size effects in systematic reviews of diagnostic test accuracy was assessed. J Clin Epidemiol 2005;58:882-893.
38. Halfon P, Bacq Y, De Muret A, Penaranda G, Bourliere M, Ouzan D, et al. Comparison of test performance profile for blood tests of liver fibrosis in chronic hepatitis C. J Hepatol 2006.;46:395-402.
39. Sebastiani G, Vario A, Guido M, Noventa F, Plebani M, Pistis R, et al. Stepwise combination algorithms of non-invasive markers to diagnose significant fibrosis in chronic hepatitis C. J Hepatol 2006;44:686-693.
40. Castera L, Vergniol J, Foucher J, Le Bail B, Chanteloup E, Haaser M, et al. Prospecrive comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C. Gastroenterology 2005;128:343-350.
41. de Ledinghen V, Douvin C, Kettaneh A, Ziol M, Roulot D, Marcellin P, et al. Diagnosis of hepatic fibrosis and cirrhosis by transient elastography in HIV/hepatitis C virus-coinfected patients. J Acquir Immune Defic Syndr 2006;41:175-179.
42. Gobel T, Vorderwulbecke S, Hauck K, Fey H, Haussinger D, Erhardt A. New multi protein patterns differentiate liver fibrosis stages and hepatocellular carcinoma in chronic hepatitis C serum samples. World J Gastroenterol 2006;12:7604-7612.
43. Fabris C, Smirne C, Toniutto P, Colletta C, Rapetti R, Minisini R, et al. Assessment of liver fibrosis progression in patients with chronic hepatitis C and normal alanine aminotransferase values: the role of AST to the platelet ratio index. Clin Biochem 2006;39:339-343.
44. Kawamoto M, Mizuguchi T, Katsuramaki T, Nagayama M, Oshima H, Kawasaki H, et al. Assessment of liver fibrosis by a noninvasive method of transient elastography and biochemical markers. World J Gastroenterol 2006;12:4325-4330.
45. Maor Y, Bashari D, Kenet G, Lubetsky A, Luboshitz J, Schapiro JM, et al. Non-invasive biomarkers of liver fibrosis in haemophilia patients with hepatitis C: can you avoid liver biopsy? Haemophilia 2006;12:372-379.
46. Yu ML, Lin SM, Lee CM, Dai CY, Chang WY, Chen SC, et al. A simple noninvasive index for predicting long-term outcome of chronic hepatitis C after interferon-based therapy. HEPATOLOGY 2006;44:1086-1097.
47. Ngo Y, Munteanu M, Messous D, Charlotte F, Imbert-Bismut F, Thabut D, et al. A prospective analysis of the prognostic value of biomarkers (FibroTest) in patients with chronic hepatitis C. Clin Chem 2006;52:1887-1896.
48. Al-Mohri H, Cooper C, Murphy T, Klein MB. Validation of a simple model for predicting liver fibrosis in HIV/hepatitis C virus-coinfected patients. HIV Med 2005;6:375-378.
49. Kelleher TB, Mehta SH, Bhaskar R, Sulkowski M, Astemborski J, Thomas DL, et al. Prediction of hepatic fibrosis in HIV/HCV co-infected patients using serum fibrosis markers: the SHASTA index. J Hepatol 2005;43:78-84.
50. Nunes D, Fleming C, Offner G, O'Brien M, Tumilty S, Fix O, et al. HIV infection does not affect the performance of noninvasive markers of fibrosis for the diagnosis of hepatitis C virus-related liver disease. J Acquir Immune Defic Syndr 2005;40:538-544.
51. Macias J, Giron-Gonzalez JA, Gonzalez-Serrano M, Merino D, Cano P, Mira JA, et al. Prediction of liver fibrosis in human immunodeficiency virus/hepatitis C virus coinfected patients by simple non-invasive indexes. Gut 2006;55:409-414.
52. Bourliere M, Penaranda G, Renou C, Botta-Fridlund D, Tran A, Portal I, et al. Validation and comparison of indexes for fibrosis and cirrhosis prediction in chronic hepatitis C patients: proposal for a pragmatic approach classification without liver biopsies. J Viral Heparol 2006;13:659-670.
53. Chrysanthos NV, Papatheodoridis GV, Savvas S, Kafiri G, Petraki K, Manesis EK, et al. Aspartate aminotransferase to platelet ratio index for fibrosis evaluation in chronic viral hepatitis. Eur J Gastroenterol Hepatol 2006;18:389-396.
54. Islam S, Antonsson L, Westin J, Lagging M. Cirrhosis in hepatitis C virus-infected patients can be excluded using an index of standard biochemical serum markers. Scand J Gastroenterol 2005;40:867-872.
55. Lieber CS, Weiss DG, Morgan TR, Paronetto F. Aspattate aminotransferase to platelet ratio index in patients with alcoholic liver fibrosis. Am J Gastroenterol 2006;101:1500-1508.
56. Berg T, Sarrazin C, Hinrichsen H, Buggisch P, Gerlach T, Zachoval R, et al. Does noninvasive staging of fibrosis challenge liver biopsy as a gold standard in chronic hepatitis C? HEPATOLOGY 2004;39:1456-1457; author reply 1457-1458.
57. Liu CH, Lin JW, Tsai FC, Yang PM, Lai MY, Chen JH, et al. Noninvasive tests for the prediction of significant hepatic fibrosis in hepatitis C virus carriers with persistently normal alanine aminotransferases. Liver Int 2006;26:1087-1094.
58. Parise ER, Oliveira AC, Figueiredo-Mendes C, Lanzoni V, Martins J, Nader H, et al. Noninvasive serum markers in the diagnosis of structural liver damage in chronic hepatitis C virus infection. Liver Int 2006;26:1095-1099.
59. Romera M, Corpas R, Romero Gomez M. Insulin resistance as a non-invasive method for the assessment of fibrosis in patients with hepatitis C: a comparative study of biochemical methods. Rev Esp Enferm Dig 2006;98:161-169.
60. Schneider AR, Teuber G, Paul K, Nikodem A, Duesterhoeft M, Caspary WF, et al. Patient age is a strong independent predictor of 13C-aminopyrine breath test results: a comparative study with histology, duplex-Doppler and a laboratory index in patients with chronic hepatitis C virus infection. Clin Exp Pharmacol Physiol 2006;33:300-304.
61. Sene D, Limal N, Messous D, Ghillani-Dalbin P, Charlotte F, Thiolliere JM, et al. Biological markers of liver fibrosis and activity as non-invasive alrernatives to liver biopsy in patients with chronic hepatitis C and associated mixed cryoglobulinemia vasculitis. Clin Biochem 2006;39:715-721.
62. Snyder N, Gajula L, Xiao SY, Grady J, Luxon B, Lau DT, et al. APRI: an easy and validated predictor of hepatic fibrosis in chronic hepatitis C. J Clin Gastroenterol 2006;40:535-542.
63. Testa R, Testa E, Giannini E, Borro P, Milazzo S, Isola L, et al. Noninvasive ratio indexes to evaluate fibrosis staging in chronic hepatitis C: role of platelet count/spleen diameter ratio index. J Intern Med 2006;260:142-150.
64. Wilson LE, Torbenson M, Astemborski J, Faruki H, Spoler C, Rai R, et al. Progression of liver fibrosis among injection drug users with chronic hepatitis C. HEPATOLOGY 2006;43:788-795.
65. Romero Gomez M, Ramirez Martin del Campo M, Otero MA, Vallejo M, Corpas R, Castellano-Megias VM. [Comparative study of two models that use biochemical parameters for the non-invasive diagnosis of fibrosis in patients with hepatitis C]. Med Clin (Barc) 2005;124:761-764.
66. Le Calvez S, Thabut D, Messous D, Munteanu M, Ratziu V, Imbert-Bismut F, et al. The predictive value of Fibrotest vs. APRI for the diagnosis of fibrosis in chronic hepatitis C. HEPATOLOGY 2004;39:862-863; author reply 863.
67. Lackner C, Struber G, Liegl B, Leibl S, Ofner P, Bankuti C, et al. Comparison and validation of simple noninvasive tests for prediction of fibrosis in chronic hepatitis C. HEPATOLOGY 2005;41:1376-1382.
68. Pavic S, Svirtlih N, Simonovic J, Boricic I. [The importance of aminotransferases and platelets count in non-invasive evaluation stages of chronic hepatitis C]. Srp Arh Celok Lek 2005;133:262-265.
69. Deeks JJ. Systematic reviews of evaluations of diagnostic and screening tests. In: Altman DG, ed. Systematic Reviews in Health Care: Meta-analysis in Context. London, UK: BMJ Books, 2001.
70. Jaeschke R, Guyatt GH, Sackett DL. Users' guides to the medical literature. III. How to use an article about a diagnostic test. B. What are the results and will they help me in caring for my patients? The Evidence-Based Medicine Working Group. JAMA 1994;271:703-707.
71. Poynard T, Halfon P, Castera L, Ratziu V, Imbert-Bismut F, Naveau S, et al. Meta-analyses du FibroTest (FT) pour le diagnostic de fibrose dans les 4 maladies du foie les plus frequentes (Abstract, Association Francaise Pour L'Etude du Foie 2006, www.biopredictive.com). Available at: http://www. biopredictive.com/infos/Docteurs/copy_of_exfile.2005-04-15.2761081870/fr/attach/ METAanalyse%20FibroTest_AFEF%20202006.pdf. Accessed December 18, 2006.
72. Gazelle GS, McMahon PM, Siebert U, Beinfeld MT. Cost-effectiveness analysis in the assessment of diagnostic imaging technologies. Radiology 2005;235:361-370.
73. Poynard T, McHutchison J, Manns M, Myers RP, Albrecht J. Biochemical surrogate markers of liver fibrosis and activity in a randomized trial of peginterferon alfa-2b and ribavirin. HEPATOLOGY 2003;38:481-492.
74. Poynard T, Munteanu M, Imbert-Bismut F, Charlotte F, Thabut D, Le Calvez S, et al. Prospective analysis of discordant results between biochemical markers and biopsy in patients with chronic hepatitis C. Clin Chem 2004;50:1344-1355.
75. Scaradavou A. HIV-related thrombocytopenia. Blood Rev 2002;16:73-76.
76. Sebastiani G, Vario A, Guido M, Alberti A. Sequential algorithms combining non-invasive markers and biopsy for the assessment of liver fibrosis in chronic hepatitis B. World J Gastroenterol 2007;13:525-531.
77. Wai CT, Cheng CL, Wee A, Dan YY, Chan E, Chua W, et al. Non-invasive models for predicting histology in patients with chronic hepatitis B. Liver Int 2006;26:666-672.